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Abstract 
A formulation based on a synthetic aminolipid containing a double-tailed with two saturated 
alkyl chains along with a non-ionic surfactant polysorbate-80 has been used to form lipoplexes 
with an antisense oligonucleotide capable of inhibiting the expression of Renilla luciferase 
mRNA. The resultant lipoplexes were characterized in terms of morphology, zeta potential, 
average size, stability and electrophoretic shift assay. The lipoplexes did not show any 
cytotoxicity in cell culture up to 150 mM concentration. The gene inhibition studies 
demonstrated that synthetic cationic vesicles based on non-ionic surfactant and the appropriate 
aminolipid play an important role in enhancing cellular uptake of antisense oligonucleotides 
obtaining promising results and efficiencies comparable to commercially available cationic 
lipids in cultured mammalian cells. Based on these results, this amino lipid moiety could be 
considered as starting point for the synthesis of novel cationic lipids to obtain potential non-
viral carriers for antisense and RNA interference therapies. 
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1. Introduction 
The discovery of antisense technology and more recently RNA interference has allowed new 
strategies in the search of novel therapeutics by controlling gene expression [1]. These 
approaches incorporate different action mechanisms than those used in conventional therapies. 
For this reason the use of nucleic acids may provide enormous benefits for therapy since they 
inhibit target proteins drugs with high specificity and also become potential units in the 
treatment of genetic disordered diseases or even in cancer [2]. 
However, there are many obstacles in developing nucleic acids into therapeutics since they are 
polyanionic macromolecules. Fortunately, chemical modifications to nucleic acid backbones 
and/or sugars have accelerated the discovery process of new compounds in addition to 
improving the properties of nucleic acids in terms of stability against nucleases [3] and 
decreasing off-targets effects [4] without losing their initial biological activities. Nevertheless, 
delivery problems continue to be the major bottleneck in the development of nucleic acids as 
drugs. 
Although viral vectors like retroviruses or adenoviruses have shown high transfection 
efficiencies and have been used in some clinical trials [5] there are concerns about the 
immunogenicity or the recombination of oncogenes that have still not been solved. 
Alternatively, non-viral vectors such as lipids [6], cell-penetrating peptides [7], polymers [8] or 
gold nanoparticles [9] have emerged as promising alternatives to safely delivering nucleic acids.  
There are two strategies used for transfecting nucleic acids with non-viral vectors. The first one 
is the use of formulations [10] which are the simplest and the fastest way to bind non-viral 
vectors to nucleic acids by taking advantage of the electrostatic interactions between them. The 
second strategy is the use of covalent approaches in which non-viral carriers and nucleic acids 
are covalently linked obtaining stable nucleic acid conjugates which improve their biological 
properties in both in vitro and  in vivo [11, 12].  
There have been great advances made in the last few years in the search for both nucleic acid 
conjugates as well as formulations for generating active complexes. In addition, there has been 
renewed interest in the development of new, more efficient and less toxic formulations for 
nucleic acid delivery. 
Since the first transfection experiments carried out by Felgner [13] demonstrated an efficient 
lipid mediated DNA-transfection by using DOTMA as a cationic lipid, a variety of synthetic 
cationic lipids have been widely used in formulation in order to deliver therapeutic 
biomolecules which are becoming promising non-viral tools for nucleic acid delivery [14]. One 
of the factors that must be considered when using cationic lipids is the tendency of positively 
charged particles to interact with plasma proteins which induce aggregation and consequently 
produce low transfection efficiencies in gene delivery [15]. The reduction of the net cationic 
charge of cationic lipids in formulation, the presence of either serum-resistant cationic lipids 
[16], an increase of lipid/DNA charge ratios [17], PEGylation [18] and finally the addition of 
helper lipids into formulations [19] are essential modifications which minimize undesirable 
effects like cell toxicity in cells and avoiding rapid plasma clearance. Despite efforts made in 
the development of new formulations or designing novel cationic lipids, obtaining effective 
non-viral carriers remains crucial for optimal gene transfection.  
The use of surfactant agents in colloidal carrier systems might mask or reduce the undesirable 
effects of cationic lipids. In addition, surfactants may also play an important role in gene 
delivery [20, 21] because the resulting complexes show a high stability. Moreover, their 
synthesis is readily scalable and the structure is comparable to liposomes. However, there are 
few studies that have analyzed the effects of such surfactants agents in gene delivery processes 
[22, 23, 24]. In an effort to develop new formulations based on non-ionic surfactant vesicles, we 
have recently reported the use of a novel formulation which is composed of a mixture of non-
ionic surfactant polysorbate-80 and a synthetic aminolipid containing a double-tailed 
hydrocarbonated alkyl chain. This demonstrated the ability to efficiently deliver plasmid DNA 
into the retina with good efficiency and low toxicity [25]. In addition, the use of cationic 
niosome formulations based on the same cationic aminolipid moiety, polysorbate-80 and 
squalene were also condensed using plasmid DNA which obtained the corresponding complexes 
and mediated delivery in several cell lines with high efficiencies [26]. These results prompted us 
to further investigate the versatility of the aforementioned surfactant formulations in order to 
encapsulate oligonucleotides and evaluate their effectiveness as a drug delivery system in 
antisense therapy.  
There are few reports in the literature describing the encapsulation of oligonucleotides with non-
ionic surfactant vesicles [27] which use (in the majority of formulations) a mixture of 
commercially available cationic lipids which deliver oligonucleotides into cells. Herein, we 
describe a formulation based on of non-ionic synthetic surfactant vesicles which contain a 
modified synthetic cationic lipid and an antisense oligonucleotide (ASO) which is designed to 
knockdown the expression of a Renilla Luciferase gene. 
The resulting lipoplexes were fully characterized in terms of zeta potential, average size, 
stability and electrophoretic shift assay. Finally, the best compositions were used to study the 
potential toxicity and transfection processes of antisense oligonucleotides mediated by 
surfactant vesicles. These results were compared to transfections that were carried out using 
commercially available cationic lipids. 
2. Materials and Methods 
2.1 Materials 
All reagents employed in this work were used as received, having an analytical grade and used 
without further purification. Polysorbate-80 (Tween-80) and 3-(4,5- dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT reagent) were purchased from Sigma-Aldrich. Antisense 
phosphorothioate oligonucleotide (sequence 5’-CGT TTC CTT TGT TCT GGA-3’) 
complementary to the mRNA of the Renilla luciferase gene targeted to a predominant accessible 
site between 20 and 40 nt was purchased from Proligo (Sigma-Aldrich). A 18-mer scrambled 
antisense oligonucleotide sequence (sequence 5’- CTG TCT GAC GTT CTT TGT-3’) was 
synthesized in-house and purified according to well-established methods (DMTon-based 
protocols). All the standard phosphoramidites and ancillary reagents used for oligonucleotide 
synthesis were purchased from Applied Biosystems or Link Technologies. The synthetic 
aminolipid, 2,3-di(tetradecyloxy)propan-1-amine was obtained as described in the literature 
[28]. Lipofectamine 2000 was purchased from Invitrogen. PBS buffer and Dulbecco’s Modified 
Eagle’s Medium (DMEM) which was supplemented with a 10% heat-inactive fetal serum 
bovine (FBS) along with distilled water (DNAse/RNAse free) were purchased from Gibco. 
Additional nuclease-free water was also prepared by using 0.1% of diethylpyrocarbonate 
(DEPC) to ensure the removal of RNase contamination, autoclaved and filtered before using. 
Luciferase assay kits were purchased from Promega. Qiagen Giga plasmid purification kit was 
purchased from Qiagen.  
2.2 Preparation of synthetic non-ionic surfactant vesicles with an antisense oligonucleotide 
(ASO) containing lipoplexes 
Non-ionic synthetic surfactant vesicles were prepared using a hydration method with 
equimolecular amounts of both the synthetic aminolipid and the non-ionic surfactant 
polysorbate-80. Specifically, equimolecular amounts containing the cationic lipid and 
polysorbate-80 (6.40 µmol) were dissolved in 1 mL of chloroform. The solvent was evaporated 
and the resulting crude was kept under vacuum overnight at room temperature. The dried lipid 
film was hydrated with 1 mL of sterile HEPES (20 nM; pH 7.4) buffer, filtered previous to use 
through a 0.2 µm membrane filter, and heated to 60 ºC for 20 minutes. The dispersion was 
vortexed and sonicated for 3 minutes before being used. 
The dispersion was resuspended in HEPES buffer at stock concentrations of 0.484 mM or 828 
µM vortexed and was sonicated (3 minutes). Cationic surfactant vesicle/antisense 
oligonucleotide complexes (lipoplexes) were then formed by adding the required amount of 
cationic lipid dispersion to aliquots containing fixed amounts of either antisense oligonucleotide 
targeting the Renilla luciferase mRNA expression or a scrambled oligonucleotide at 14:1 or 
16:1 charge ratios ([cationic amino groups]cationic lipid/[anionic phosphate groups]nucleic acid, 
respectively. The resultant lipoplexes were vortexed and sonicated for 2 minutes and finally 
incubated at 37 ºC for 30 minutes.  
2.3 Morphology of lipoplexes 
The morphology of the resulted lipoplexes was assessed by Transmission Electron 
Microscopy (TEM). Briefly, 5 μl of the sample were adhered onto glow discharged carbon 
coated grids for 60 s. The remaining liquid was removed by blotting on a paper filter and 
stained with 2% uranyl acetate for 60 seconds. Samples were observed under the microscope, 
TECNAI G2 20 TWIN (FEI, Eindhoven, The Netherlands), operating at an accelerating voltage 
of 200 KeV in a bright-field image mode. Digital images were acquired with an Olympus SIS 
Morada digital camera. 
2.4 Electrophoretic mobility shift assay 
Antisense oligonucleotide (0.5 µM) was mixed with increasing concentrations of the cationic 
surfactant dispersion giving rise to cationic vesicle/antisense oligonucleotide molar ratios 
ranging from 2 to 20. Lipoplexes were analyzed using electrophoresis on a 20% polyacrylamide 
gel at 150 V for 5 hours in TBE buffer 1X. Pictures were taken using Fujifilm LAS-1000 
Intelligent Dark Box II using IR LAS-1000 Lite v1.2 
2.5 Zeta potential  
Zeta potential values were obtained by laser doppler velocimetry by using a Zetasizer Nano ZS 
(Malvern Instruments) equipped with a He-Ne red light laser (l = 633 nm). All measurement 
parameters and the sample preparation (0.5 µM of antisense oligonucleotide in a final volume of 
50 µL) were carried out according to the experimental procedure described before. Studies in 
the presence of fetal serum bovine (FBS) were carried out by adding 5 µL of FBS to the 
lipoplex solutions (50 µL) followed by 5 minutes of incubation. In both cases, the resulting 
lipoplex solutions were diluted with mili-Q water to a final volume of 1 mL. Data is shown as 
the average value of three runs.  
2.6 Size measurement and physical stability of vesicles 
The particle size of cationic vesicles and cationic vesicle/antisense oligonucleotide lipoplexes 
were determined by using a dynamic light scattering (DLS) spectrometer (LS Instruments, 3D 
cross correlation multiple-scattering) equipped with a He-Ne laser (632.8 nm) with variable 
intensity. Cationic surfactant vesicles were stored at 4 ºC and stability studies of cationic 
surfactant vesicle/antisense oligonucleotide complexes were carried out by analyzing the 
average size of the particles at room temperature by dynamic light scattering for one month. In 
both cases, cationic vesicles and lipoplexes were previously sonicated and measurements were 
taken at a scattering angle of 90º, in triplicates, without diluting samples and at a constant 
temperature of 25ºC. The particle radius was calculated by fitting of the first cumulant 
parameter. 
2.7 Cell culture 
HeLa cells were cultured at 37ºC, 5% CO2 in DMEM partially supplemented with 10% fetal 
bovine serum, 100 mg/mL penicillin and 100 µg/mL streptomycin. Cells were regularly 
passaged in order to maintain exponential growth. Twenty-four hours before transfection at 40 
to 80% confluency, cells were trypsinized and diluted 1:5 with a fresh medium without 
antibiotics (about 1-3 x 105 cells/mL) and transferred to a 24-well plate (500 µL per well). Two 
luciferase plasmids, Renilla luciferase (pRL-TK) and Firefly luciferase (pGL3) from Promega, 
were used as a reporter and as a control, respectively. Renilla and Firefly luciferase vectors (0.1 
µg and 1.0 µg per well, respectively) were transfected into the cells using Lipofectamine 2000. 
Cells were incubated with the plasmids for 5 hours. The medium was discarded and cells were 
washed with PBS twice (500 µL). Then, 500 µL of fresh DMEM without antibiotics were added 
to each well. Two transfection experiments were carried out using either DMEM without FBS 
or DMEM supplemented with 10% of FBS. Then antisense oligonucleotides were prepared at 
concentrations of 20, 60, 100 and 150 nM, respectively. Lipoplexes (300 µL) (which were 
prepared according to the procedure described before), were previously incubated for 30 min at 
37°C using HEPES buffer (20mM, pH 7.4). Later, 100 μL of antisense oligonucleotide and 
scrambled lipoplexes were added to each well. Cell lysates were prepared and analyzed twenty-
four hours after transfection using the Dual-Luciferase Reporter Assay System according to the 
manufacturer’s protocol. Lumminiscence was measured using SpectraMax M5 
spectrophotometer. 
2.8 Analysis of cell viability by the MTT colorimetric assay 
HeLa cells viability in the presence of both cationic vesicles and lipoplexes were tested at 
different concentrations (20, 60, 100 and 150 nM, respectively) using the MTT colorimetric 
assay. For each assay, cells were seeded (about 6 x 103 cells per well) on a 96-well plate in 200 
µL of DMEM and cultured for 24h. Later, the culture medium was discarded and both vesicles 
and lipoplexes were added at gradually larger concentrations between 20 and 150 nM. Cells 
were incubated for 4h at 37ºC under 5% CO2 atmosphere. The media was discarded and 
additional DMEM (200 µL) was added. Cells were incubated for 15 hours at 37°C. The MTT 
reagent was added at a final concentration of 0.5 mg/mL per (25 µL) and incubated for two 
additional hours at 37°C. Finally, the medium was absorbed, DMSO (200 µL) and was added to 
dissolve formazan crystals (15 minutes of stirring at room temperature) and absorbance (l = 
570 nm) was measured. Absorbance was measured using SpectraMax M5 spectrophotometer. 
3. Results 
3.1 Morphology of the lipoplexes 
TEM pictures showed that lipoplexes at 14/1 N/P ratio exhibited a discrete spherical 
morphology and did not aggregate under our experimental conditions (Fig. 1). Particle size of 
resulting lipoplexes was around 200 nm. 
3.2 Zeta potential measurements and oligonucleotide binding capacity measurements 
Cationic surfactant vesicle/antisense oligonucleotide lipoplexes were characterized in terms of 
Zeta potential and oligonucleotide binding capacity. Non-ionic surfactant synthetic vesicles 
composed of a modified amino lipid with a double-tailed hydrocarbonated alkyl chain and 
polysorbate-80 were used at several ratios ranging from 1 to 20 and using a fixed amount of 
antisense oligonucleotide (0.5 µM) in order to determine the optimal charge ratio to form 
lipoplexes in serum-free conditions. As depicted in Fig. 2A, the Zeta potential displayed 
negative values at the lowest N/P charge ratios (-20 mV for a N/P charge ratio of 2) due to the 
presence of the negatively charged antisense oligonucleotide. Clearly, as the concentration of 
cationic vesicles increased, the tendency of Zeta potential changed by decreasing this negative 
character in the system and thereby obtained positive values in a range of +12 mV to +20 mV 
indicating an electrostatic stabilization level. The effect of fetal bovine serum (FBS) in the 
cationic vesicles was also evaluated (Fig. 2A). As expected, all charge ratios that were tested 
displayed similar behaviors in the presence of FBS. They obtained negative Zeta potential 
values close to -18 mV, except for charge ratios of 14 and 16, in which there was a slight 
increase that reached values of the Zeta potential between -14 and -12 mV, respectively.  
These results clearly indicate that all charge ratios were serum-dependent in which negatively 
charged particles of serum were absorbed onto the surface of lipoplexes. Moreover, these results 
may suggest that the exact influence of serum might be dependent on the charge ratio of the 
cationic vesicles. Alternatively, a native electrophoretic gel assay of lipoplexes was also carried 
out in order to confirm at which N/P ratio oligonucleotides are complexed with our cationic 
surfactant vesicles. As illustrated in Fig. 2B, free DNA and complexes can be separated by 
native polyacrylamide gel electrophoresis. Free ASO oligonucleotide is observed in N/P charge 
ratios from 0 to 8. When ASO oligonucleotide is complexed with the cationic vesicles, the 
resulting complexes do not enter the gel because of the size restriction. The ASO 
oligonucleotide was retained in wells from N/P charge ratios 10 to 18 indicating complete 
complexation.  
3.3 Particle size and physical stability of cationic vesicles 
Besides the characterization of lipoplexes by superficial charge and the evaluation of their 
binding capacity to antisense oligonucleotides, dynamic light scattering (DLS) was also used to 
measure the average particle size of cationic surfactant vesicle/antisense oligonucleotide 
complexes at charge N/P ratios of 14 and 16 along with the stability evaluation of the cationic 
surfactant complexes stored at 4ºC for one month. Physical characterization of cationic 
surfactant vesicle/antisense oligonucleotide complexes in terms of Zeta potential and average 
size is displayed in Table 1. The average particle size of both N/P ratios was almost identical 
(ranging from 324 and 334 nm for charge ratios of 14 and 16, respectively). As illustrated in 
Fig. 3, the average size of the complex remained practically constant for one month, according 
to DLS measurements. 
3.4 Cell culture 
3.4.1 Transfection activity in serum-free conditions 
We first evaluated the transfection efficiencies at several N/P ratios (12, 14, 16, 18 and 20-fold, 
respectively) of our cationic surfactant vesicle/antisense oligonucleotide which formed 
complexes in serum-free medium conditions in order to determine which charge ratio would be 
more effective at carrying out gene transfection experiments, as shown in Fig. 4. All selected 
N/P ratios were able to silence gene expression in a range of 50 to 70% of inhibition at 60 nM. 
In particular, we observed good efficiencies for charge ratios of 12, 14 16 and 18 obtaining 
similar silencing activities (63, 70, 69 and 68% respectively) whereas lower transfection 
efficiencies were observed at a charge ratio of 20 which reached only 51% of luciferase 
inhibition. Therefore, we chose selected charge ratios of 14 and 16 to evaluate the effect of both 
cationic surfactant vesicles and antisense oligonucleotide forming complexes on cell viability 
and gene transfection, respectively. 
3.4.2 Cytotoxicity assay 
Cell viability and cytotoxicity studies were carried out (previous to cell transfection 
experiments) by incubating HeLa cells with cationic surfactant vesicle dispersion and lipoplexes 
at both charge ratios of 14 and 16, respectively. They contained different concentrations of 
antisense oligonucleotide (20, 60, 100 and 150 nM, respectively) in the presence of DMEM 
supplemented with serum (10%) by using a tetrazolium-based colorimetric assay [29]. As 
depicted in Fig. 5, no significant toxicity was observed in cells compared with control samples 
in the presence of either cationic surfactant vesicles or lipoplexes formed with a charge ratio of 
14, which obtained viabilities around 90% in all tested concentrations. HeLa cells in the 
presence of lipoplexes formed at a N/P charge ratio of 16 displayed a concentration-dependent 
toxicity which did not show any cytotoxicity at low concentrations (around 90 and 80% of cell 
viability at 20 and 60 nM, respectively) whereas the aforementioned lipoplexes were 
detrimental at high concentrations (100 and 150 nM) to cell viability (40%) probably due to an 
increase of polysorbate-80 content in the composition of the surfactant dispersion. Cell viability 
was also compared to positive controls by using Lipofectamine (Figure S2; Supplementary 
Part). Lipoplexes at a charge ratio of 14 along with cells in the presence of Lipofectamine did 
not show any cytotoxicity at the tested concentrations. Consequently, all further studies in cell 
culture were therefore performed at a charge ratio of 14. 
3.4.3 In vitro transfection: Evaluation of the antisense activity 
The efficiency in the transfection of cationic surfactant vesicle/antisense oligonucleotide 
complexes at the optimal charge ratio of 14 was carried out at several concentrations (20, 60, 
100 and 150 nM, respectively) targeting the Renilla luciferase mRNA expression in the absence 
of a commercially available cationic lipids. We observed that complexes were able to mediate 
cellular uptake and hence exhibited high efficiencies in gene transfection at both 100 and 150 
nM (83% and 87% for 100 and 150 nM, respectively). Lipoplexes were also able to silence 
luciferase expression at 20 and 60 nM (4% and 60% for 20 and 60 nM, respectively). A 
phosphorothioate scrambled sequence forming complexes with cationic vesicles at the same 
charge ratio of 14 had no effect on luciferase expression at the same tested concentrations 
thereby indicating the specificity of the gene knockdown experiment (Fig. 6).  
The transfection efficiencies mediated by our cationic surfactant vesicles dispersion at their 
optimal N/P ratio were compared to commercially available cationic lipids like Lipofectamine, 
as a positive control, at concentrations of 20, 60, 100 and 150 nM. As illustrated in Fig. 7, gene 
transfections carried out in the presence of Lipofectamine were more efficient only at 60 nM 
(84% versus 60% for Lipofectamine and cationic surfactant vesicles, respectively). However, 
both systems reached a plateau at higher concentrations (100 and 150 nM), and hence obtained 
similar gene knockdown activities (approximately 85% of luciferase inhibition).  
3.4.4 Effect of the fetal bovine serum (FBS) on transfection experiments 
In order to evaluate the effect of serum on cellular uptake, we studied the efficiency of cationic 
vesicle/antisense oligonucleotide complexes at a charge ratio of 14 to mediate cellular uptake at 
several FBS concentrations (0, 10, 40 and 60%, respectively) at 60 nM. The results depicted in 
Fig. 8 showed a clear reduction in the transfection efficiency at high FBS concentrations 
although cellular uptake was not totally inhibited (23% for FBS at 60%). In contrast, while the 
use of lower FBS concentrations (10%) promoted similar transfection efficiencies than in the 
absence of serum (from 70% to 60% of gene knockdown activity), cellular uptake experiments 
carried out with FBS at 40% caused a 2-fold decrease in luciferase inhibition activity (36% 
reduction) in comparison with the maximal efficiency achieved in serum-free conditions. These 
results demonstrated the dependency of cationic lipoplexes at their optimal N/P ratio in the 
presence of high serum concentration and their efficiencies on cellular transfection. 
4. Discussion 
The emergence of new therapies such as antisense technology or more recently RNA 
interference has allowed therapeutic oligonucleotides to be seen as promising units for fighting 
against several diseases because of their high specificity in the inhibition of target proteins. 
However, it is also well-known that delivery of nucleic acids is the major challenge because 
they have to cross several cellular barriers including plasma membrane. Low cellular uptake is 
the main bottleneck for the development of nucleic acids as therapeutics.  
Consequently, the development of new drug delivery systems that may facilitate cellular uptake 
of nucleic acids is becoming necessary. Herein, we described a novel non-viral carrier based on 
the use of a formulation made up of a synthetic aminolipid and non-ionic surfactant 
polysorbate-80 which were able to form vesicles and consequently were able to form complexes 
with antisense oligonucleotides and mediate delivery in cell culture.  
It is well-reported in literature that encapsulating oligonucleotides in lipid vesicles may turn out 
to be a limiting step in the development of an effective formulation. Although there are several 
techniques to improve the efficiency in encapsulation of oligonucleotides [30] herein, we used 
hydration of lipid films as the main approach for forming stable cationic vesicle/oligonucleotide 
complexes.  
To get a direct evidence of the lipoplexes formation, we examined such lipoplexes at 14/1 N/P 
ratio under TEM at different magnifications Fig. 1. Adding oligonucleotides to our formulation 
resulted in lipoplexes which did not aggregate to our experimental conditions (Fig 1-A). These 
lipoplexes adopted spherical morphology, the most favorable structure conformation from an 
energetic point of view. Lipoplexes size was around 200 nm, slightly smaller than the size 
reported by dynamic light scattering in Table 1 (320 nm). At high magnification (Fig 1B), small 
cavities were displayed in the lipoplexes. The heterogeneous distribution of the oligonucleotides 
during the spontaneously and self-assembly process might cause such cavities. 
We characterized which N/P ratio between cationic vesicles and antisense oligonucleotides was 
the optimal way to form complexes with a range of 0 to 20-fold. The antisense oligonucleotide 
was partly condensed by the synthetic aminolipid unit after adding 6-fold of cationic dispersion, 
according to Zeta potential and electrophoretic mobility shift assay experiments. Increasing N/P 
ratios from 12 to 20, more amino groups were introduced to bind to antisense oligonucleotides 
and thereby lead to the formation of the expected cationic surfactant vesicle/antisense 
oligonucleotide complexes with an increase of surface charge reaching a plateau at a charge 
ratio of 20. 
One of the existing milestones in gene transfection is the effect induced by negatively charged 
plasma proteins on the surface of cationic lipoplexes which are prone to aggregation and lead to 
the failure of cell transfection. Antisense oligonucleotide forming complexes in a selected range 
of charge ratios from 12 to 20 were evaluated to promote delivery in the absence of fetal bovine 
serum in order to know the best N/P ratio for carrying out cell transfection. All tested N/P ratios 
were able to impart cellular uptake, being charge ratios of 14 and 16 those which obtained the 
best transfection efficiencies and silencing activities than the rest of the selected N/P ratios. 
In order to correctly explain our cellular uptake results, we first evaluated whether the viability 
of HeLa cells were not affected with the use of our cationic surfactant vesicles as well as 
lipoplexes using the MTT colorimetric assay. Although some surfactants are seldom used in cell 
culture due to their toxicity [31], cationic vesicle dispersions along with lipoplexes at the charge 
ratio of 14 did not induce any cytotoxicity in HeLa cells at the selected concentrations. 
However, in the case of using lipoplexes at the N/P ratio of 16, lipoplexes did not display any 
cytoxicity effect at lower concentrations (20 and 60 nM) whereas toxicity of the aforementioned 
lipoplexes was detrimental at higher concentrations (100 and 150 nM) which had a significant 
negative effect on cell growth at the same charge ratio of 16. This was probably due to the toxic 
effect induced by our cationic vesicle formulation and surfactant agent proportions used [31] to 
form lipoplexes with antisense oligonucleotides. 
Cellular uptake experiments mediated by cationic surfactant vesicle/antisense oligonucleotide 
complexes at their optimal N/P ratio of 14 triggered in a dose-response manner the best gene 
knockdown activities at 100 and 150 nM. These silencing activities were comparable when 
commercially available cationic lipids were also used at the same tested concentrations. These 
results suggest that this transfection properties mediated by our surfactant lipoplexes might be 
due to structural changes caused in either the morphology or phase evolution of lipoplexes and 
their possible ability to undergo a lamellar to non-lamellar phase transition [32]. 
Another factor that can limit the effectiveness of cellular uptake is the presence of negatively 
charged serum proteins in medium due to the tendency of these particles to interact with the 
cationic charged surface of vesicles that induce aggregation in the system and deactivate their 
internalization into cells. This serum-dependence of cationic lipoplexes causes a serious 
limitation for in vivo applications and hence reduces the efficacy of the non-viral vector in gene 
therapy. In order to overcome this unwanted effect, authors have described some strategies like 
the use of serum-resistance amino acid-based cationic lipids [16], the use of PEGylated 
synthetic surfactant vesicles [22], the addition of helper lipids [19] or PEGylated lipids [33]. All 
these modifications have shown an improvement in the potency and stability of the formulation 
and an increase in the cellular uptake carried out by DNA complexes. Transfection experiments 
mediated by our surfactant cationic vesicle/antisense oligonucleotide complexes (as expected) 
were dependent as FBS concentration increased. In our hands, the efficacy in the transfection 
process of cationic particles at the optimal N/P ratio diminished obtaining only 20% of 
luciferase inhibition when a high concentration of FBS (60%) was used. In the case of using low 
serum levels (10 or 40%, respectively) better transfection results were achieved, as was 
expected. These results are in accordance to the literature in which the use of non-ionic 
surfactant molecules such as sorbitan monoesters (Spans) or polysorbate-80 (Tween-80) to 
stabilize cationic formulations normally have shown poor efficiency in the presence of a high 
concentration of serum [34].  
There is a general consensus in which endocytosis mechanism has been proposed as the major 
mode of action of lipoplex-mediated delivery antisense oligonucleotide [35, 36] although other 
kinds of mechanisms like fusion have been suggested as well [37]. It is also well-accepted that 
the type of endocytosis can also depend on the particle size [38] and the net positive charged 
surfaces of non-viral carriers [39] which may interact with the negative charges at the cell 
surface and consequently release the genetic cargo from endosomes. However, despite all 
efforts and studies carried out to understand how this cellular entry pathway works for nucleic 
acid forming complexes, knowledge of their uptake mechanism is still limited [40]. According 
to our results, the average size of cationic surfactant vesicle/antisense oligonucleotide 
complexes at their optimal charge ratios of 14 and 16 gave similar sizes of around 320 nm. This 
result may suggest a receptor-mediated endocytosis through the clarthrin-mediated pathway [41] 
as the main entering pathway for the aforementioned cationic surfactant lipoplexes by ensuing 
membrane destabilization and leading to the release of antisense oligonucleotides and therefore 
efficiently inhibit gene expression [34].  
5. Conclusions 
The urge to obtain new vehicles capable of improving the delivery properties of nucleic acids is 
essential for the development of oligonucleotide-based therapeutics. Cationic liposomes 
composed of helper lipids like DOPE or cholesterol are normally used for stabilizing complexes 
with nucleic acids and consequently often increase their transfection potencies. In this article, 
we used a formulation based on a modified aminolipid containing two saturated alkyl chains 
and a non-ionic surfactant polysorbate-80 in order to form stable modified cationic vesicles with 
antisense oligonucleotides. Lipoplexes were characterized in terms of Zeta potential and 
dynamic light scattering. Furthermore, the ability of these surfactant cationic vesicle/antisense 
oligonucleotide complexes to impart cellular uptake in cell culture was also evaluated. The 
results confirmed that lipoplexes at their optimal N/P ratio of 14 did not show any sign of 
cytotoxicity in cell culture except for lipoplexes with a charge ratio of 16 in which cell viability 
was compromised. Lipoplexes showed a clear serum-dependence at high serum concentrations 
however, the use of low serum conditions (10%) on our modified cationic surfactant vesicles 
promoted comparable results in cellular uptake to those obtained with commercially available 
cationic lipids. We believe that the presence of the modified amino containing a double-tailed 
hydrocarbonated lipid chain may be considered as a starting point in order to design novel 
cationic lipids by modifying some elements such as headgroup or a glycerol backbone and lead 
to the study the subsequent structure-activity relationship for the development of new gene 
delivery systems. 
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Average size measurements by Dinamic Light Scattering at a charge ratio of 16 and normalized 
cell viability by MTT assay. 
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Fig. 1 TEM images of lipoplexes at 14/1 N/P ratio, original magnification 7.100x (A) and 88.000x 
(B).
 
 
Fig. 2. Zeta potential of cationic vesicle/antisense oligonucleotide (ASO) lipoplexes at several 
N/P charge ratios in the absence (circles) and the presence (triangles) of fetal bovine serum 
(FBS) (A) and the characterization of lipoplexes by electrophoretic mobility shift assay (B). 
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Table 1 
Physical characterization (size and Zeta potential) of cationic vesicle lipoplexes containing an 
antisense oligonucleotide at N/P charge ratios of 14 and 16. Results are means ±S.D. for three 
independent experiments. 
Cationic surfactant vesicle / antisense oligonucleotide complexes 
N/P charge ratio 14 16 
size (nm) 324 ±32.0 332±3.0 
ζ potential (mV) 19.3±0.61 13.2±2.0 
 
Fig. 3. Physical stability measurements of cationic vesicle/antisense oligonucleotide (ASO) 
lipoplexes at a N/P charge ratio of 14 by dynamic light scattering for one month.  
 
 
Fig. 4. Normalized transfection efficiencies mediated by cationic vesicle/antisense 
oligonucleotide lipoplexes targeting Renilla luciferase mRNA in serum-free conditions at 
several charge ratios at 60 nM. Antisense oligonucleotide (ASO) in the absence of non-viral 
carrier was evaluated as a control. Results are means ±S.D. for three independent experiments. 
 
 
Fig. 5. Normalized cell viability of both cationic vesicle dispersions and antisense 
oligonucleotide forming lipoplexes at charge ratios of 14 and 16. Results are means ±S.D. for 
nine independent experiments. 
 
 
Fig. 6. Normalized gene-specific silencing activities targeting Renilla luciferase mRNA for 
cationic vesicle/antisense oligonucleotide (ASO) lipoplexes at a charge ratio of 14 at several 
concentrations (20, 60, 100 and 150 nM, respectively). Antisense oligonucleotide at the same 
tested concentrations in the absence of a non-viral carrier along with a scramble sequence (Scr) 
forming lipoplexes were used as controls. Results are means ±S.D. for three independent 
experiments. 
 
 
Fig. 7. Normalized gene-specific silencing activities targeting Renilla luciferase mRNA for 
cationic vesicles containing unmodified antisense oligonucleotide (ASO) at a N/P charge ratio 
of 14. Comercially available lipofectamine was used as a positive control at several 
concentrations (20, 60, 100 and 150 nM, respectively). Results are means ±S.D. for three 
independent experiments. 
 
 
Fig. 8. Effect of fetal bovine serum (0 to 60%) on cell transfection mediated by cationic 
vesicle/antisense oligonucleotide (ASO) lipoplexes at a N/P charge ratio of 14. Antisense 
oligonucleotide in the absence of non-viral carrier was used as a control. Results are means 
±S.D. for three independent experiments. 
 
 
 
